Handy del Sol Bello

"With a proven track record of excellence in the pharmaceutical industry, I bring a unique combination of innovative thinking, and a commitment to quality. My experience in drug development, regulatory compliance, and market strategy ensures that I can contribute significantly to your company's growth and success. Together we will drive forward groundbreaking solutions that improve lives worldwide."

Experienced in clinical trial coordination, adept at reviewing medical histories, conducting interviews, and assessing participant eligibility. Skilled in scheduling and maintaining communication with participants, ensuring seamless study visits. Proven ability to document recruitment progress and manage patient recruitment strategies, resulting in enhanced enrollment rates and streamlined study timelines. Collaborates effectively with cross-functional teams to monitor study progress and implement corrective actions.

• FIBROSCAN SUPERUSER OPERATOR, 07/01/26
• CITI GOOD CLINICAL PRACTICE (GCP), 06/28/26
• BASIC LIFE SUPPORT (BLS), 06/28/26
• ADVANCED CARDIOVASCULAR LIFE SUPPORT (ACLS), 06/27/26
• DATA MANAGEMENT AND ELECTRONIC DATA CAPTURE (EDC), 07/05/26
• REGULATORY COMPLIANCE AND INVESTIGATOR RESPONSIBILITIES, 06/28/26
• IATA (DANGEROUS GOODS), 06/28/26
• OSHA (OCCUPATIONAL SAFETY & HEALTH ADMINISTRATION), 06/27/26

• Spanish
• English, Superior
• Spanish, Superior

• D5982C00006 (ASTRAZENECA), A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY), 2025 to present
• D5241C00007 (ASTRAZENECA), A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma, 2023 to present
• D9181C00002 (ASTRAZENECA), A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL), 2025 to present
• 2023 to present, A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort Turbuhaler in Participants with Inadequately Controlled Asthma (VATHOS)
• 2023 to present, A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS)
• GSK4532990 Injection (GlaxoSmithKline), A Phase 2a, single dose, open-label, dose-exploration study to assess the PK-PD activity, safety, and tolerability of GSK4532990 in adult participants with NASH or suspected NASH, 2023 to present
• BOS-580-201 (BOSTON PHARMACEUTICALS), A PHASE 2, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, 48-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF COMBINATION THERAPY OF K877-ER AND CSG452 IN PATIENTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH LIVER FIBROSIS, 2024 to present
• 2023 to present, A Phase 2a, randomized, blinded, placebo-controlled study of BOS-580 in obese subjects at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH) with a single arm open-label extension
• 2023 to present, A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis